AmTrust Financial Services, Inc. (NASDAQ:AFSI) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with -18.65% to $17.58. Pomerantz LLP declared that a class action lawsuit has been filed against AmTrust Financial Services, Inc. (AFSI) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 17-cv-01545, is on behalf of a class consisting of investors who purchased or otherwise acquired AmTrust securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) AmTrust had ineffective assessment of the risks associated with its financial reporting; (ii) the Company had an insufficient complement of corporate accounting and corporate financial reporting resources within the organization; (iii) in turn, the Company lacked effective internal controls over financial reporting; and (iv) as a result of the foregoing, AmTrust’s public statements were materially false and misleading at all relevant times. The share price of AFSI attracts active investors, as stock price of week volatility recorded 4.23%. The stock is going forward to its 52-week low with -16.92% and lagging behind from its 52-week high price with -37.89%.
Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) [Trend Analysis] moved down reacts as active mover, shares a decrease -33.68% to traded at $0.24 and the percentage gap between open changing to regular change was -23.43%. Northwest Biotherapeutics (NWBO) reported that it has entered into definitive contracts with institutional investors for a registered direct offering with gross proceeds of $7.5 millionIn the transaction, the Company will sell approximately 28.8 million shares of common stock at a purchase price of $0.26 per share, or pre-funded warrants in lieu of shares.
Additionally, the investors will receive five year Class A warrants to purchase up to approximately 21.6 million shares of common stock with an exercise price of $0.26 per share. They also will receive three month Class B warrants to purchase up to approximately 21.6 million shares of common stock with an exercise price of $1.00 per share. Finally, in lieu of shares, to the extent required to prevent the beneficial ownership of an investor, together with affiliates, of our Common Stock from exceeding 4.99%, investors will receive pre-funded Class C warrants which are exercisable immediately.